CD47 x guide arm #3

**CD47 x guide arm #3** is a preclinical bispecific antibody being developed by Virtuoso Therapeutics for solid tumors. Based on the company pipeline, the molecule is designed to engage **CD47** together with an undisclosed second binding arm referred to only as **guide arm #3**. The likely intended biology is tumor-directed blockade or modulation of the CD47 innate immune checkpoint while using the proprietary guide arm to bias binding toward selected tumor tissue, but the identity of the guide-arm target and the exact mechanism have not been publicly disclosed. The asset appears to be an investigational oncology immunotherapy program and no clinical-stage code name, brand name, dosing form, route, or manufacturer details have been publicly identified.

Other names

Virtuoso Therapeutics-CD47-guide arm #3-bispecific antibody-Solid Tumor (cancer)